What is Chardan Capital’s Estimate for CRSP FY2024 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research report issued on Wednesday, November 6th. Chardan Capital analyst Y. Livshits now forecasts that the company will earn ($4.84) per share for the year, up from their prior forecast of ($5.75). Chardan Capital currently has a “Buy” rating and a $94.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.23) per share. Chardan Capital also issued estimates for CRISPR Therapeutics’ FY2025 earnings at ($4.62) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the prior year, the company posted ($1.41) EPS.

Other research analysts have also issued research reports about the company. Truist Financial reduced their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus cut their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $74.94.

CRISPR Therapeutics Stock Up 6.3 %

Shares of CRISPR Therapeutics stock opened at $54.86 on Monday. CRISPR Therapeutics has a fifty-two week low of $43.42 and a fifty-two week high of $91.10. The firm has a market cap of $4.68 billion, a PE ratio of -19.39 and a beta of 1.67. The business’s fifty day moving average is $47.60 and its two-hundred day moving average is $52.16.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Global Trust Asset Management LLC grew its stake in CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC lifted its holdings in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC lifted its holdings in CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after acquiring an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in CRISPR Therapeutics in the second quarter worth about $35,000. Finally, Orion Capital Management LLC lifted its holdings in CRISPR Therapeutics by 44.0% in the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after acquiring an additional 220 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.